MBX Biosciences, Inc. MBX
50.33 USD +1.87 (+3.85%)
Nov 6, 2026, 10:43 AM EST
48.44 Day range 50.34
21.90 52-week range 72.64
- YTD
- +59.56%
- 1 year
- +103.42%
Financial health
Altman Z-Score
52.48 Safe zone
Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.
Piotroski F-Score
1 / 9 Weak
Nine pass/fail tests of profitability, leverage and efficiency.
Rating
C2 / 5 overall
- DCF 2
- Return on Equity 1
- Return on Assets 1
- Debt / Equity 4
- P/E 1
- P/B 1
Valuation
P/E -13.3×
FY 2022 5y median -18.2× FY 2025
P/S 0.0×
FY 2022 5y median 0.0× FY 2025
P/B 3.1×
FY 2022 5y median -4.0× FY 2025
P/FCF -14.1×
FY 2022 5y median -18.8× FY 2025
EV/EBITDA -12.4×
FY 2022 5y median -17.4× FY 2025
EV/Sales 0.0×
FY 2022 5y median 0.0× FY 2025
FCF Yield -7.1%
FY 2022 5y median -5.7% FY 2025
Profitability
Gross Margin 0.0%
FY 2022 5y median 0.0% FY 2025
Operating Margin 0.0%
FY 2022 5y median 0.0% FY 2025
Net Margin 0.0%
FY 2022 5y median 0.0% FY 2025
ROE -23.6%
FY 2022 5y median 10.7% FY 2025
ROIC -26.5%
FY 2022 5y median -35.2% FY 2025
ROA -22.6%
FY 2022 5y median -30.9% FY 2025
Growth (YoY)
Revenue 0.0%
FY 2022 FY 2025
Operating Income -43.8%
FY 2022 FY 2025
EPS (diluted) -28.6%
FY 2022 FY 2025
Free Cash Flow -47.4%
FY 2022 FY 2025
Financial Health
Current Ratio 24.6×
FY 2022 5y median 22.7× FY 2025
Quick Ratio 24.6×
FY 2022 5y median 22.7× FY 2025
Debt / Equity 0.0×
FY 2022 5y median -0.0× FY 2025
Net Debt / EBITDA 0.9×
FY 2022 5y median 0.9× FY 2025
Interest Coverage 0.0×
FY 2022 5y median 0.0× FY 2025
Dividends
Dividend Yield 0.0%
FY 2022 5y median 0.0% FY 2025
Payout Ratio 0.0%
FY 2022 5y median 0.0% FY 2025
Annual · latest fiscal year ends 2025-12-31